This inventor holds 7 USPTO granted patents and 2 EPO patents. Top assignees: Ptc Therapeutics, Inc., Daifuku Co., Ltd., Sumitomo Pharma Co., Ltd.. Active years: 2017-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 186 
2 out of 710 
2 out of 66 Years Active: 2017-2025
Title: Kazuto Mori: Innovator in Pharmaceutical Compounds
Introduction
Kazuto Mori is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in developing compounds that address various diseases. With a total of 7 patents, Mori's work is recognized for its potential therapeutic applications.
Latest Patents
Mori's latest patents include a 2-heteroaryl aminoquinazolinone derivative. This compound is represented by a specific formula and is designed to be a pharmaceutically acceptable salt. Additionally, he has developed 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds, which are aimed at treating mitochondrial or oxidative stress diseases such as cancer, Alzheimer's disease, and Parkinson's disease.
Career Highlights
Throughout his career, Kazuto Mori has worked with notable companies such as PTC Therapeutics, Inc. and Sumitomo Pharma Co., Ltd. His innovative approach and dedication to research have positioned him as a key figure in pharmaceutical development.
Collaborations
Mori has collaborated with esteemed colleagues, including Hiroyuki Kitano and Tomoyuki Furuta. These partnerships have further enhanced his research and contributions to the field.
Conclusion
Kazuto Mori's work in developing pharmaceutical compounds showcases his commitment to addressing critical health challenges. His innovative patents and collaborations highlight his significant impact on the industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile